celivarone: Clinical Trials

5 completed. 5 Phase 2, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	5	Completed 5
Phase 3	1	Completed 1

Follow celivarone: new trials by email Literature Review of celivarone trials Research Report on celivarone

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death Celivarone, Amiodarone, Matching placebo - Arrhythmia Prophylaxis, Ventricular Arrhythmia	Phase 2	Completed	Sanofi	486	2009-09-01	2016-05-30
Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers ATI-2042, ATI-2042 200 mg - Atrial Fibrillation	Phase 2	Completed	ARYx Therapeutics	72	2006-07-01	2009-03-11
Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr CELIVARONE (SSR149744C) - Atrial Fibrillation, Atrial Flutter	Phase 2	Completed	Sanofi	150	2005-10-01	2012-05-08
Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS SSR149744C - Arrhythmia, Tachycardia, Ventricular	Phase 2	Completed	Sanofi	153	2005-06-01	2012-05-08
Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 mg OD With Amiodarone as Calibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/Flutter CELIVARONE (SSR149744C) - Atrial Fibrillation, Atrial Flutter	Phase 2 / Phase 3	Completed	Sanofi	673	2004-12-01	2012-05-08

Conditions studied

Atrial Fibrillation (3)  ·  Arrhythmias, Cardiac (2)  ·  Atrial Flutter (2)  ·  Tachycardia, Ventricular (1)  ·  Ventricular Fibrillation (1)

Sponsors

Sanofi (4)  ·  ARYx Therapeutics (1)

Countries

Canada (5)  ·  United States (5)  ·  Germany (4)  ·  Italy (4)  ·  Netherlands (4)  ·  Czechia (3)  ·  France (3)  ·  Hungary (3)  ·  Argentina (2)  ·  Australia (2)  ·  Belgium (2)  ·  Chile (2)  ·  Denmark (2)  ·  Japan (2)  ·  Poland (2)

Top investigators

Michael Ezekowitz, MBChB, PhD (1)  ·  Olga Bandman, MD (1)

Results publications

PMID 22171925, PMID 21978965, PMID 22082672

NIH funding

2008 (1)